Skip to main content

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Changes in Scientific Management Team

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is making changes in its scientific management team. The company announced that Michael Palfreyman, PhD, and Brett Greene, both of whom joined Cybin as part of the acquisition of Adelia Therapeutics, will be moving into advisory roles; the company noted that Alex Nivorozhkin, PhD, will continue as Cybin’s chief scientific officer. The changes come as final milestones identified by the contribution agreement between Cybin and Adelia Therapeutics have been reached. Since the acquisition, Palfreyman has been serving as Cybin’s chief R&D officer and Greene had been serving as chief innovations officer. “We are extremely grateful for the opportunity to work with Mike and Brett, whose deep knowledge of psychedelics and drug development has helped Cybin to advance its programs quickly and efficiently to the clinic,” said Cybin CEO Doug Drysdale in the press release. “The Adelia acquisition was highly successful, providing us with many of the tools needed to accelerate our programs through the clinic and progressing our novel psychedelic-based therapeutics for patients in need. Cybin and Adelia established ambitious goals at the time of the acquisition, and Mike and Brett were integral to achieving them. We look forward to their continued contributions in their new roles as advisors to Cybin.”

To view the full press release, visit https://ibn.fm/FChk7

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.